KTOV News and Press, Kitov Pharma Ltd.

REHOVOT, Israel, Jan. 18, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech”) (NASDAQ/TASE: PPBT), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced that the Purple Biotech manageme...

Virtual Bell-Ringing Ceremony in Celebration of Company’s Recent Name Change to Purple Biotech REHOVOT, Israel, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (the “Company”) (NASDAQ/TASE: PPBT), a clinical-stage company advancing first-in-class thera...

Kitov Pharma ([[KTOV]] -0.2%) announces corporate name change from Kitov Pharma to Purple Biotech Ltd.The name change will be effective for trading purposes on the Tel Aviv Stock Exchange and NASDAQ as of market open on December 22, 2020.Company’s ordinary shares and American...

New Name Reflects Company’s Evolution to Advancing First-in-Class Oncology Therapies TEL AVIV, Israel, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (the “Company”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to o...

TEL AVIV, Israel, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced that management will present at the H.C. Wainw...

TEL AVIV, Israel, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced that the company and Bristol Myers Squibb ...

Kitov has lost momentum after a rally in June where the company announced a key partnership with Bristol-Myers in a lung cancer co-study. Since, shareholders have been diluted on the back of management's decision for a shelf registration of depository receipts in August. We've see...

The USPTO has issued a Notice of Allowance to Kitov Pharma (KTOV) for a patent application entitled “Combinations of IRS/STAT3 Dual Modulators and Anti-Cancer Agents for Treating Cancer”.The patent which expires in 2036, covers the various combinations of NT219 with multiple 2nd...

Patent covers NT219’s combinations with multiple 2 nd and 3 rd generation EGFR inhibitors, including osimertinib (TAGRISSO®) TEL AVIV, Israel, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV)...

Socket Mobile (SCKT) +123% on Q3 results.Dogness (DOGZ) +60% after announcing partnership with Hangzhou Huayuan Pet Products and Shanghai Chongai Trading Co. Ltd.Zedge (ZDGE) +47% on Q4 results.Solid Biosciences (SLDB) +28% on announcing collaborat...